Literature DB >> 15150122

UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.

Maria M Facchinetti1, Adriana De Siervi, Doreen Toskos, Adrian M Senderowicz.   

Abstract

The small molecule UCN-01 is a cyclin-dependent kinase (CDK) modulator shown to have antiproliferative effects against several in vitro and in vivo cancer models currently being tested in human clinical trials. Although UCN-01 may inhibit several serine-threonine kinases, the exact mechanism by which it promotes cell cycle arrest is still unclear. We have reported previously that UCN-01 promotes G(1)-S cell cycle arrest in a battery of head and neck squamous cancer cell lines. The arrest is accompanied by an increase in both p21(waf1/cip1) and p27(kip1) CDK inhibitors leading to loss in G(1) CDK activity. In this report, we explore the role and the mechanism for the induction of these endogenous CDK inhibitors. We observed that p21 was required for the cell cycle effects of UCN-01, as HCT116 lacking p21 (HCT116 p21(-/-)) was refractory to the cell cycle effects of UCN-01. Moreover, UCN-01 promoted the accumulation of p21 at the mRNA level in the p53-deficient HaCaT cells without increase in the p21 mRNA half-life, suggesting that UCN-01 induced p21 at the transcriptional level. To study UCN-01 transcriptional activation of p21, we used several p21(waf1/cip1) promoter-driven luciferase reporter plasmids and observed that UCN-01 activated the full-length p21(waf1/cip1) promoter and a construct lacking p53 binding sites. The minimal promoter region required for UCN-01 (from -110 bp to the transcription start site) was the same minimal p21(waf1/cip1) promoter region required for Ras enhancement of p21(waf1/cip1) transcription. Neither protein kinase C nor PDK1/AKT pathways were relevant for the induction of p21 by UCN-01. In contrast, the activation of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase mitogen-activated protein kinase pathways was required for p21 induction as UCN-01 activated this pathway, and genetic or chemical MEK inhibitors blunted p21 accumulation. These results demonstrated for the first time that p21 is required for UCN-01 cell cycle arrest. Moreover, we showed that the accumulation of p21 is transcriptional via activation of the MEK pathway. This novel mechanism, by which UCN-01 exerts its antiproliferative effect, represents a promising strategy to be exploited in future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150122     DOI: 10.1158/0008-5472.CAN-03-3741

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  ERK mediates anti-apoptotic effect through phosphorylation and cytoplasmic localization of p21Waf1/Cip1/Sdi in response to DNA damage in normal human embryonic fibroblast (HEF) cells.

Authors:  Jee-In Heo; Soo-Jin Oh; Yoon-Jung Kho; Jeong-Hyeon Kim; Hong-Joon Kang; Seong-Hoon Park; Hyun-Seok Kim; Jong-Yeon Shin; Min-Ju Kim; Sung Chan Kim; Jae-Bong Park; Jaebong Kim; Jae-Yong Lee
Journal:  Mol Biol Rep       Date:  2010-11-26       Impact factor: 2.316

2.  PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Authors:  Crissy Dudgeon; Peng Wang; Xiameng Sun; Rui Peng; Quanhong Sun; Jian Yu; Lin Zhang
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

3.  Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

Authors:  Jolyn Turner; Constantinos Koumenis; Timothy E Kute; Roy P Planalp; Martin W Brechbiel; Dillon Beardsley; Brooke Cody; Kevin D Brown; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

Review 4.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

5.  Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.

Authors:  Laura A Marlow; Jaclyn D'Innocenzi; Yilin Zhang; Stephen D Rohl; Simon J Cooper; Thomas Sebo; Clive Grant; Bryan McIver; Jan L Kasperbauer; J Trad Wadsworth; John D Casler; Pamela W Kennedy; W Edward Highsmith; Orlo Clark; Dragana Milosevic; Brian Netzel; Kendall Cradic; Shilpi Arora; Christian Beaudry; Stefan K Grebe; Marc L Silverberg; David O Azorsa; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2010-09-01       Impact factor: 5.958

6.  The ETS family transcription factor ELK-1 regulates induction of the cell cycle-regulatory gene p21(Waf1/Cip1) and the BAX gene in sodium arsenite-exposed human keratinocyte HaCaT cells.

Authors:  Soon Young Shin; Chang Gun Kim; Yoongho Lim; Young Han Lee
Journal:  J Biol Chem       Date:  2011-06-03       Impact factor: 5.157

Review 7.  Modeling resistance to pathway-targeted therapy in ovarian cancer.

Authors:  Deyin Xing; Sandra Orsulic
Journal:  Cell Cycle       Date:  2005-08-25       Impact factor: 4.534

8.  Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme.

Authors:  Débora G Salomón; María E Fermento; Norberto A Gandini; María J Ferronato; Julián Arévalo; Jorge Blasco; Nancy C Andrés; Jean C Zenklusen; Alejandro C Curino; María M Facchinetti
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

9.  Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro.

Authors:  S Madlener; P Saiko; C Vonach; K Viola; N Huttary; N Stark; R Popescu; M Gridling; N T-P Vo; I Herbacek; A Davidovits; B Giessrigl; S Venkateswarlu; S Geleff; W Jäger; M Grusch; D Kerjaschki; W Mikulits; T Golakoti; M Fritzer-Szekeres; T Szekeres; G Krupitza
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

10.  Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

Authors:  Yun Dai; Shuang Chen; Xin-Yan Pei; Jorge A Almenara; Lora B Kramer; Charis A Venditti; Paul Dent; Steven Grant
Journal:  Blood       Date:  2008-07-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.